Download our whitepaper,
Neuropathic pain arises from damage or dysfunction of the nervous system, leading to chronic pain conditions that significantly impact patients’ quality of life. Clinical trials in this area focus on evaluating the efficacy and safety of novel analgesics and treatment strategies.
Over the years, advancements in understanding the pathophysiology of neuropathic pain have informed the development of targeted therapies. Clinical trial designs have evolved to incorporate patient-reported outcomes, biomarker assessments, and adaptive methodologies to enhance trial success.
iNGENū’s expertise in neuropathic pain clinical trials enables us to design and execute studies that address the unique challenges of this field. By leveraging our deep understanding of pain mechanisms and regulatory requirements, we aim to accelerate the development of effective treatments for patients suffering from neuropathic pain.
Approximately
7-10%
of the general population suffers from neuropathic pain
Neuropathic pain accounts for about
20-30%
of chronic pain cases seen in clinical practice
Clinical trials in neuropathic pain have a success rate of around
15-20%
reflecting the complexity of pain mechanisms
iNGENū’s clinical team has over
120 years
of combined clinical trial experience